Future IPO candidate

Elpiscience needs more funds for cancer research

Backed by Lilly Asia Ventures and Hillhouse, Elpiscience wants to attract more funding to develop the best-in-class solution for cancer treatment.

Carol Huang

July 07, 2019

China-based immune-oncology company Elpiscience is currently raising Series B funding which it hopes to complete within the next couple of months.

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].